Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous ...

Nothing drives down a drug’s price like competition. According the U.S. Food and Drug Administration (FDA), a drug’s ...

Merck already has the world’s biggest selling oral treatment for type 2 diabetes, its DPP-4-based drugs Januvia and Janumet, but it is playing catch-up in the SGLT2 market. The monotherapy and ...

Metabolic diseases is already a focus area for Merck & Co – it markets several diabetes drugs including Januvia (sitagliptin) and last year exercised an option to develop NGM313, an antibody ...

The rise of GLP-1s, which were initially approved for diabetes management and later for obesity treatment, underscores this ...

Merck's revenue increase was primarily due to raised sales of its anticancer medications ... as well as its diabetes franchise. However, this decline, in my opinion, is not critical for Merck's ...

Merck is also seeing weakness in the diabetes franchise and the generic erosion of some drugs. Merck’s shares have lost 23.5% in the past year compared with a decrease of 4.3% for the industry.

Rising competitive pressure on the diabetes franchise and persistent ... better analyze how to play Merck stock. Merck boasts more than six blockbuster drugs in its portfolio, with blockbuster ...